PRODUCT RANGE

Taj Group of Companies
TAJ PHARMACEUTICALS LTD.

Etanercept. FDA-approved to treat rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis.



Moderate to Severe Plaque Psoriasis

ENBROL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

* In medical studies, nearly half of patients saw a significant improvement in their plaque psoriasis within 3 months of using ENBROL. Overall, 3 out of 4 patients saw improvement. ENBROL can work fast; many patients saw improvement within 2 months. ENBROL has been shown to be effective through 12 months of therapy.

ENBROL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body makes called TNF. Tumor necrosis factor is made by your body's immune system. People with immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis have too much TNF in their bodies.



^{*} Not open to uninsured patients or patients eligible for or covered by federal, state, or government-funded insurance programs (for example, Medicare, Medicaid, etc) or patients who live in Massachusetts (or where prohibited by law). Restrictions, including monthly maximums, may apply. Offer subject to change or discontinuation without notice.